Skip to main content
Clinical Trials/JPRN-jRCTs031180256
JPRN-jRCTs031180256
Active, not recruiting
Phase 3

TRANSPERINEAL PROSTATE BRACHYTHERAPY, USING I-125 SEED WITH OR WITHOUT ADJUVANT ANDROGEN DEPRIVATION, IN PATIENTS WITH INTERMEDIATE-RISK PROSTATE CANCER: STUDY PROTOCOL FOR A PHASE III, MUTICENTER, RANDOMIZED, CONTROLLED TRIAL - SHIP0804

Egawa Shin0 sites420 target enrollmentMarch 13, 2019

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Egawa Shin
Enrollment
420
Status
Active, not recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 13, 2019
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
Male

Investigators

Sponsor
Egawa Shin

Eligibility Criteria

Inclusion Criteria

  • 1\.Prostate cancer classified as an intermediate risk group from clinical stage, PSA value, Gleason score of central pathology diagnosis.
  • 2\. Be previously untreated Pca.
  • 3\. ECOG PS is 0 or 1
  • 4\.The age at consent acquisition is between 20 years old and 75 years old.
  • 5\.Laboratory test values satisfy the following criteria.
  • 1\) White blood cell count over 3000 / myu L
  • 2\) Hemoglobin over 10\.0 g / dL
  • 3\) Number of platelets over 100000 / myu L
  • 4\) Serum creatinine under 2\.0 mg / dL
  • 5\) AST (GOT) under 100 IU / L

Exclusion Criteria

  • 1\. Have PSA over 20 ng/mL.
  • 2\. Have a biopsy Gleason score over 8\.
  • 3\. Exhibit clinical stage over T2c.
  • 4\. Have a second cancer that requires treatment.
  • 5\. Have poorly\-controlled hypertension (diastolic pressure over 120mmHg)
  • 6\. Have a severe psychiatric disorder, including schizophrenia and dementia.
  • 7\. Have collagen disease diabetes.
  • 8\. Have poorly\-controlled diabetes.
  • 9\. Have previously received surgery for PCa.
  • 10\. Are using steroid drugs other than topical ointments.

Outcomes

Primary Outcomes

Not specified

Similar Trials